Savara (SVRA) Short term Debt (2015 - 2022)
Savara (SVRA) reported Short term Debt of $12.5 million for Q1 2022, up 50.01% on a QoQ basis from $8.3 million in Q4 2021.
Savara (SVRA) has 7 years of Short term Debt data on file, last reported at $12.5 million in Q1 2022.
- Quarterly Short term Debt changed N/A year-over-year to $12.5 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $12.5 million (changed N/A YoY) and the FY2021 annual result came in at $8.3 million, changed N/A from the prior year.
- Short term Debt advanced to $12.5 million in Q1 2022 per SVRA's latest filing, from $8.3 million in the prior quarter.
- Across five years, Short term Debt topped out at $12.5 million in Q1 2022 and bottomed at $1.9 million in Q2 2018.
- The 4-year median for Short term Debt is $4.0 million (2018), against an average of $5.4 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 12.50 Mn |
| Dec 31, 2021 | 8.33 Mn |
| Sep 30, 2021 | 4.17 Mn |
| Dec 31, 2019 | 2.00 Mn |
| Sep 30, 2018 | 3.75 Mn |
| Jun 30, 2018 | 1.88 Mn |
| Mar 31, 2017 | 1.58 Mn |
| Dec 31, 2016 | 1.55 Mn |
| Sep 30, 2016 | 11.59 Mn |
| Jun 30, 2016 | 12.51 Mn |
| Mar 31, 2016 | 11.45 Mn |
| Dec 31, 2015 | 10.99 Mn |
| Sep 30, 2015 | 1.54 Mn |